Joseph W Fay
Overview
Explore the profile of Joseph W Fay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1023
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pan D, Kaufman J, Htut M, Agrawal M, Mazumder A, Cornell R, et al.
Cancer Med
. 2021 Dec;
11(2):358-370.
PMID: 34921527
Filanesib is a first-in-class kinesin spindle protein inhibitor which demonstrated safety and encouraging activity in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma in a preliminary analysis of dose-escalation...
2.
Radivoyevitch T, Dean R, Shaw B, Brazauskas R, Tecca H, Molenaar R, et al.
Leuk Res
. 2018 Jul;
74:130-136.
PMID: 30055822
Background: Exposures to DNA-damaging drugs and ionizing radiations increase risks of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Methods: 9028 recipients of hematopoietic cell autotransplants (1995-2010) for Hodgkin lymphoma...
3.
Chari A, Suvannasankha A, Fay J, Arnulf B, Kaufman J, Ifthikharuddin J, et al.
Blood
. 2017 Jun;
130(8):974-981.
PMID: 28637662
Daratumumab plus pomalidomide and dexamethasone (pom-dex) was evaluated in patients with relapsed/refractory multiple myeloma with ≥2 prior lines of therapy who were refractory to their last treatment. Patients received daratumumab...
4.
Chari A, Htut M, Zonder J, Fay J, Jakubowiak A, Levy J, et al.
Cancer
. 2016 Jul;
122(21):3327-3335.
PMID: 27433944
Background: Filanesib is a kinesin spindle protein inhibitor that has demonstrated encouraging activity in patients with recurrent/refractory multiple myeloma. Preclinical synergy with bortezomib was the rationale for the current phase...
5.
Flowers C, Costa L, Pasquini M, Le-Rademacher J, Lill M, Shore T, et al.
Biol Blood Marrow Transplant
. 2016 Apr;
22(7):1197-1205.
PMID: 27040394
Busulfan, cyclophosphamide, and etoposide (BuCyE) is a commonly used conditioning regimen for autologous stem cell transplantation (ASCT). This multicenter, phase II study examined the safety and efficacy of BuCyE with...
6.
Armand P, Nagler A, Weller E, Devine S, Avigan D, Chen Y, et al.
J Clin Oncol
. 2013 Oct;
31(33):4199-206.
PMID: 24127452
Purpose: The Programmed Death-1 (PD-1) immune checkpoint pathway may be usurped by tumors, including diffuse large B-cell lymphoma (DLBCL), to evade immune surveillance. The reconstituting immune landscape after autologous hematopoietic...
7.
Van Besien K, Carreras J, Bierman P, Logan B, Molina A, King R, et al.
Biol Blood Marrow Transplant
. 2009 Apr;
15(5):554-63.
PMID: 19361747
We analyzed the outcomes of 283 patients receiving unrelated donor allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma (NHL) facilitated by the Center for International Blood and Marrow Transplant Research/National Marrow...
8.
Martin P, Storer B, Rowley S, Flowers M, Lee S, Carpenter P, et al.
Blood
. 2009 Mar;
113(21):5074-82.
PMID: 19270260
We conducted a double-blind, randomized multicenter trial to determine whether the addition of mycophenolate mofetil (MMF) improves the efficacy of initial systemic treatment of chronic graft-versus-host disease (GVHD). The primary...
9.
Vence L, Palucka A, Fay J, Ito T, Liu Y, Banchereau J, et al.
Proc Natl Acad Sci U S A
. 2007 Dec;
104(52):20884-9.
PMID: 18093940
Although it is accepted that regulatory T cells (T regs) contribute to cancer progression, most studies in the field consider nonantigen-specific suppression. Here, we show the presence of tumor antigen-specific...
10.
Palucka A, Ueno H, Fay J, Banchereau J
Immunol Rev
. 2007 Nov;
220:129-50.
PMID: 17979844
Immunotherapy seeks to mobilize a patient's immune system for therapeutic benefit. It can be passive, i.e. transfer of immune effector cells (T cells) or proteins (antibodies), or active, i.e. vaccination....